Immunogenicity and Safety Assessment of Rabies Vaccine (Vero Cell) for Human Use, Freeze-dried

Inclusion Criteria: 1. Aged 10-60 years at enrollment; 2. Volunteers and/or their guardians voluntarily agree to participate in the study and sign the ICF. 3. Volunteers and their families can comply with the protocol requirements for study follow-up (no plans for long-term absence or relocation from the study area); 4. Female volunteers are not pregnant or lactating (negative urine pregnancy test before vaccination) and have no pregnancy plan within 2 months after enrollment; 5. Axillary temperature ≤ 37.2°C. Exclusion Criteria: 1. History of injection with rabies vaccine and specific passive immune preparations, or history of dog or other mammal bites/scratches (Category II exposure or above) within the past year; 2. History of severe allergies requiring medical intervention from previous vaccinations; other severe allergies, such as allergic shock, angioneurotic edema, allergic purpura, local allergic necrotic reaction (Arthus reaction), severe urticaria, and angioneurotic edema; 3. Pyrexia (axillary temperature \> 38.5°C) within 3 days before the first dose vaccination; suffering from acute or chronic infectious diseases (active tuberculosis, viral hepatitis) or in the acute exacerbation phase of any chronic disease; 4. Having received blood/blood-related products or immunoglobulins within 3 months before the first dose vaccination; or planning to use such products within 1 month after the last dose vaccination; 5. Having received live attenuated vaccine within 14 days or any vaccine within 7 days before the first dose vaccination; 6. Any condition (e.g., splenectomy) leading to asplenia or functional asplenia; 7. Diagnosed with congenital or acquired immunodeficiency (HIV), or received immunosuppressant therapy within 3 months (e.g., long-term systemic glucocorticoid use ≥ 14 days, dose ≥ 2 mg/kg/day or ≥ 20 mg/day prednisone or equivalent); 8. Severe congenital anomaly, autoimmune disease, genetic disease; severe heart disorder, kidney disease, diabetes, or other severe chronic disease; 9. History of convulsion, epilepsy, or psychotic disorder; 10. Contraindications for intramuscular injection (e.g., diagnosed thrombocytopenia, any coagulopathy, or anticoagulant therapy); 11. Hypertension unable to be controlled with drugs, such as systolic blood pressure ≥160 mmHg and/or diastolic blood pressure ≥100 mmHg during physical examination before enrollment (for adults aged 18 and above); 12. Currently participating in a clinical study of another investigational or unregistered product (drug or vaccine) or planning to participate in other clinical studies before the end of this clinical study; 13. Any condition of the volunteer that may interfere with the assessment of the study purpose as deemed by the investigator.